Delivering complete aseptic vial handling solutions
Bringing freeze drying and vial washing/sterilizing technologies together with advanced and comprehensive vial and syringe filling capabilities.
SP Scientific has signed a new partnership agreement with Lab-i-DOSiTECNO Pharma Technologies enabling both companies to offer complete aseptic vial and syringe fill-finish lines lines for injectable, ophthalmic and oral products in liquid and powder form.
This new global partnership brings together best-in-class freeze drying and vial washing/sterilizing technologies from SP Scientific with the advanced and comprehensive vial and syringe filling capabilities of Lab-i-DOSiTECNO.
Oriol Casòliva, CEO of Lab-i-DOSiTECNO commented: “The geographic synergies of SP Scientific and Lab-iDosiTECNO working together will enable us to provide outstanding local support throughout North America and Europe, significantly broadening the reach of both partners.”
Brian Larkin, CEO of SP Scientific added: “In addition, for those who prefer to work with a single supplier for full lines, this new partnership enables us to provide and support these customers with top quality, highly productive aseptic fill-finish line solutions."
Biopharmaceutical products are often frozen and then thawed, freeze-dried to be rehydrated when needed, or encapsulated in liquid form without being touched by the atmosphere. The container that holds the medicine during transportation through a variety of global climates, and how it is filled, is therefore critical to product integrity. SP Scientific, in partnership with Lab-i-DOSiTECNO, now leads the way in the development and manufacture of complete aseptic vial fill-finish lines offering the broadest lyophilization range available today covering cycle development, stability, pilot and clinical batch production, through to full aseptic manufacturing and commercial production batches.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...